RMD had been plaqued by interested parties down ramping the...

RMD had been plaqued by interested parties down ramping the shares (while buying it) every time a GLDP-1 wonder drugs report fabulous profits. It happens so regularly and yet some shareholders keep falling for the tricks. Longer term shareholders are well aware of these tricks and had been kept informed by RMD in tracking the GLDP-1s effect on CPAP patient numbers showing the funelling effect - I am not convinced by the "tail wind" effect as there are other factors that may have contributed to the increase such as:

• Due to the shortage & demand for GLDP1s wonder drugs, the manufacturers have kept the price at a premium and the consumers on the wonder drugs are not your average person - they are economically advantaged/ rich to afford the drugs and hence they are also likely to afford the CPAP treatment.
• RMD is having a dream run with the major competitor Pillips still out of the market from the fall-out of the faulty device recall.

Having said the above, the potential sleep apnea market is huge with only a small fraction of sufferers diagnosed and treated. RMD is by far the fore runner in the sleep apnea market. The Q3 results were fabulous by any measure.
Investors also took note of Software-as-a-Service revenue increased by 8 percent, reflecting the continued organic growth in the SaaS portfolio.

There are plenty to like in RMD as a long term quality company.
Long term shareholders should look out for opportunities each time interested parties down ramp the sp whenever a pharmaceutical company releases a super profit from the price gouching GLDP1s wonder drugs - Eli Lilly wont be the last, it is a regular trick that will come as long as there are sunrises and sun sets.